-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Contrasting LENSAR (NASDAQ:LNSR) & InspireMD (NYSE:NSPR)
Contrasting LENSAR (NASDAQ:LNSR) & InspireMD (NYSE:NSPR)
LENSAR (NASDAQ:LNSR – Get Rating) and InspireMD (NYSE:NSPR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Earnings and Valuation
This table compares LENSAR and InspireMD's revenue, earnings per share and valuation.
Get LENSAR alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $34.46 million | 1.81 | -$19.60 million | ($2.40) | -2.36 |
| InspireMD | $4.49 million | 3.28 | -$14.92 million | ($2.22) | -0.80 |
InspireMD has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
56.0% of LENSAR shares are owned by institutional investors. Comparatively, 2.1% of InspireMD shares are owned by institutional investors. 19.0% of LENSAR shares are owned by insiders. Comparatively, 3.8% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.Analyst Ratings
This is a breakdown of current ratings and target prices for LENSAR and InspireMD, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 0 | 0 | 2 | 0 | 3.00 |
| InspireMD | 0 | 0 | 0 | 0 | N/A |
LENSAR currently has a consensus price target of $14.00, suggesting a potential upside of 147.35%. Given LENSAR's higher possible upside, equities research analysts clearly believe LENSAR is more favorable than InspireMD.
Risk and Volatility
LENSAR has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Profitability
This table compares LENSAR and InspireMD's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | -63.71% | -45.47% | -37.06% |
| InspireMD | -334.66% | -54.85% | -46.01% |
Summary
LENSAR beats InspireMD on 8 of the 13 factors compared between the two stocks.
About LENSAR
(Get Rating)
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
About InspireMD
(Get Rating)
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
LENSAR (NASDAQ:LNSR – Get Rating) and InspireMD (NYSE:NSPR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
纳斯达克(Sequoia Capital：LNSR-GET Rating)和InspirreMD(NYSE：NSPR-GET Rating)都是小盘医疗公司，但哪种投资更好？我们将根据这两家公司的收益、盈利能力、风险、分析师建议、股息、估值和机构所有权等方面的实力进行比较。
Earnings and Valuation
收益和估值
This table compares LENSAR and InspireMD's revenue, earnings per share and valuation.
该表格比较了LENSAR和InspirreMD的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $34.46 million | 1.81 | -$19.60 million | ($2.40) | -2.36 |
| InspireMD | $4.49 million | 3.28 | -$14.92 million | ($2.22) | -0.80 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| LENSAR | 3,446万美元 | 1.81 | -1,960万元 | ($2.40) | -2.36 |
| InspirreMD | 449万美元 | 3.28 | -1,492万元 | ($2.22) | -0.80 |
InspireMD has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
InspirreMD的收入低于LENSAR，但收益高于LENSAR。LENSAR的市盈率低于InSpireMD，这表明它目前是两只股票中更负担得起的一只。
Institutional & Insider Ownership
机构与内部人持股
Analyst Ratings
分析师评级
This is a breakdown of current ratings and target prices for LENSAR and InspireMD, as provided by MarketBeat.
这是由MarketBeat提供的LENSAR和InspirreMD的当前评级和目标价格的细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 0 | 0 | 2 | 0 | 3.00 |
| InspireMD | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| LENSAR | 0 | 0 | 2 | 0 | 3.00 |
| InspirreMD | 0 | 0 | 0 | 0 | 不适用 |
LENSAR currently has a consensus price target of $14.00, suggesting a potential upside of 147.35%. Given LENSAR's higher possible upside, equities research analysts clearly believe LENSAR is more favorable than InspireMD.
LENSAR目前的普遍目标价为14.00美元，暗示潜在上行147.35%。考虑到LENSAR较高的可能上行空间，股票研究分析师显然认为LENSAR比InspirreMD更有利。
Risk and Volatility
风险和波动性
LENSAR has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
LENSAR的贝塔系数为-0.11，这意味着其股价的波动性比标准普尔500指数低111%。相比之下，InSpireMD的贝塔系数为1.27，这意味着其股价的波动性比标准普尔500指数高27%。
Profitability
盈利能力
This table compares LENSAR and InspireMD's net margins, return on equity and return on assets.
此表比较了LENSAR和InspirreMD的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | -63.71% | -45.47% | -37.06% |
| InspireMD | -334.66% | -54.85% | -46.01% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| LENSAR | -63.71% | -45.47% | -37.06% |
| InspirreMD | -334.66% | -54.85% | -46.01% |
Summary
摘要
LENSAR beats InspireMD on 8 of the 13 factors compared between the two stocks.
在比较两只股票的13个因素中，LENSAR在8个因素上击败了InspirreMD。
About LENSAR
关于LENSAR
(Get Rating)
(获取评级)
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR，Inc.是一家商业阶段的医疗设备公司，专注于设计、开发和销售一种飞秒激光系统，用于治疗白内障和管理先前存在的或手术引起的角膜散光。其LENSAR激光系统结合了一系列专有技术，旨在通过提供成像、程序规划、设计和精度来帮助外科医生获得可视结果、效率和重复性。该公司成立于2004年，总部设在佛罗里达州奥兰多。
About InspireMD
关于InspirreMD
(Get Rating)
(获取评级)
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
InspirreMD公司是一家医疗设备公司，专注于开发专有的MicroNet支架平台技术并将其商业化，用于治疗欧洲、拉丁美洲、中东和亚太地区的血管和冠状动脉疾病。该公司提供用于颈动脉应用的CGuard颈动脉血栓预防系统，以及用于急性冠脉综合征患者的MGuard Prime血栓保护系统，特别是急性心肌梗死、大隐静脉移植冠状动脉介入治疗以及搭桥手术。它还在开发PVGuard，一种用于外周血管应用的MicroNet网状套筒和自膨胀支架。该公司通过当地分销商销售其产品。InspirreMD，Inc.成立于2005年，总部设在以色列特拉维夫-亚福。
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
接受《LENSAR日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对LENSAR和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧